Copyright
©The Author(s) 2024.
World J Orthop. Sep 18, 2024; 15(9): 870-881
Published online Sep 18, 2024. doi: 10.5312/wjo.v15.i9.870
Published online Sep 18, 2024. doi: 10.5312/wjo.v15.i9.870
Table 2 Designs and conclusions of included studies
Ref. | Study design | Sample size | Age (mean) | BMI (mean) | Female | Pathology | Intervention (s) | Latest follow-up | Outcomes measured | Conclusion |
Becker et al[15] | Randomized prospective cohort study | ACS: n = 32, 5 mg Triamcinolone: n = 27, 10 mg Triamcinolone: n = 25 | 53.9 (range: 29-81) | Not reported | 38.10% | Lumbar radiculopathy | 3 weekly transforaminal injections of ACS, 5 mg triamcinolone, or 10 mg triamcinolone | 20 weeks post-final injection | VAS, ODI | Epidural ACS injection for unilateral lumbar radiculopathy significantly improved patient pain and disability compared to baseline to an extent potentially superior to ESI. No statistically significant difference in symptom improvement was observed between 5 mg and 10 mg epidural injection of triamcinolone |
Goni et al[16] | Pilot study | ACS: n = 20; MPS: n = 20 | ACS: 42.25; MPS: 46.80 | Not reported | ACS: 40%; MPS: 45% | Cervical radiculopathy | A single 2-3 mL transforaminal injection of ACS or MPS | 6 months post-injection | VAS, NDI, NPDS, PCS, MCS | Patients with cervical radiculopathy treated with epidural ACS injection experienced sustained improvement of pain, disability and quality of life. ACS produced as good or better improvement of symptoms with longer duration of relief compared to epidural methylprednisolone |
HS et al[17] | Prospective study | ACS: n = 20 | 37.15 | 24.92 kg/m2 | Not reported | Lumbar radiculopathy | A single 2 mL transforaminal injection of ACS | 6 months post-injection | VAS, SLRT, ODI, PCS, MCS | Epidural ACS injection can modify the disease course of unilateral lumbar radiculopathy by significantly improving pain, disability, and quality of life |
Godek et al[19] | Pilot study | ACS: n = 15 | 38.8 | Not reported | 40% | Lumbar radiculopathy | 1-2 weekly transforaminal injections of 3-4 mL ACS | 6 months post-injection | VAS, ODI, SLRT, OLST, Analgesic use | ACS is a promising option for significantly improving pain and disability in patients with single-level lumbar radiculopathy. No radicular damage or sever adverse events were reported |
Godek et al[18] | Retrospective study | ACS: n = 497 | 57.1 ± 16.5 (range: 17-93) | Not reported | 57.70% | Cervical DDD (transforaminal injection): n = 89. Thoracic Spine DDD (transforaminal injection): n = 8. Lumbar Spine DDD (transforaminal injection): n = 271. Lumbar Spine DDD (interlaminar injection): n = 1. Lumbar Spine Stenosis (transforaminal injection): n = 118. Lumbar Spine Stenosis (interlaminar injection): n = 10 | Cervical: 4 doses of 3-4 mL transforaminal ACS injections. Thoracic: 6 doses of 3-4 mL transforaminal ACS injections. Lumbar: 4-6 doses of 4 mL ACS injected transforaminally or interlaminarly | 6 months post-final injection | Modified McNabb scale | ACS injection was well tolerated with very few and limited cases of adverse events. ACS injection produced satisfactory improvement in Modified McNabb Scale scores for patients with cervical or lumbar discopathy. Unsatisfactory results predominated in cases of lumbar spinal stenosis |
Godek et al[13] | Randomized control trial | ACS: n = 100 | 46.29 + 13.61 | 26.67 ± 4.49 | 51% | Lumbar Radiculopathy due to DDD (interlaminar injection): n = 50. Lumbar Radiculopathy due to DDD (transforaminal injection): n = 50 | 2 weekly interlaminar or transforaminal injections of 8 mL ACS | 24 weeks post-final injection | NRS, ODI, RMQ, EQ-5D-5 L mobility, EQ-5D-5 L self-care, EQ-5D-5 L usual activities, EQ-5D-5 L pain/discomfort, EQ-5D-5 L anxiety/depression, EQ-5D-5 L-based LSS, EQ-5D-5 L VAS, EQ-5D-5 L Index | Epidural and transforaminal ACS injections both significantly improve patient outcomes compared to baseline. Treatment with transforaminal ACS injection produced statistically superior improvement in EQ-5D-5 L scores compared to epidural ACS injection |
- Citation: Rajkovic CJ, Merckling ML, Lee AW, Subah G, Malhotra A, Thomas ZD, Zeller SL, Wainwright JV, Kinon MD. Conservative management of spinal pathology with autologous conditioned serum: A systematic review of the literature. World J Orthop 2024; 15(9): 870-881
- URL: https://www.wjgnet.com/2218-5836/full/v15/i9/870.htm
- DOI: https://dx.doi.org/10.5312/wjo.v15.i9.870